Gyre Therapeutics (GYRE) Amortizatization of Intangibles (2010 - 2015)
Gyre Therapeutics (GYRE) reported Amortizatization of Intangibles of $63000.0 for Q2 2015, down 72.12% year-over-year from $226000.0 in Q2 2014, and down 35.05% on a QoQ basis from $97000.0 in Q1 2015.
Gyre Therapeutics (GYRE) has 6 years of Amortizatization of Intangibles data on file, last reported at $63000.0 in Q2 2015.
- Quarterly Amortizatization of Intangibles fell 72.12% year-over-year to $63000.0 in Q2 2015, while the trailing twelve-month figure through Jun 2015 was $484000.0 (down 41.62% YoY) and the FY2014 annual result came in at $775000.0, down 14.65% from the prior year.
- Amortizatization of Intangibles eased to $63000.0 in Q2 2015 per GYRE's latest filing, from $97000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $335000.0 in Q3 2011 and bottomed at $63000.0 in Q2 2015.
- The 5-year median for Amortizatization of Intangibles is $225500.0 (2013), against an average of $205055.6.
- The widest annual swing landed in 2011, when Amortizatization of Intangibles soared 125.0%; it then plunged 72.12% in 2015.
- Tracing GYRE's Amortizatization of Intangibles over 5 years: stood at $270000.0 in 2011, then slipped by 23.33% to $207000.0 in 2012, then increased by 10.14% to $228000.0 in 2013, then tumbled by 37.72% to $142000.0 in 2014, then plunged by 55.63% to $63000.0 in 2015.
- Per Business Quant, the three latest GYRE Amortizatization of Intangibles figures stand at $63000.0 (Q2 2015), $97000.0 (Q1 2015), and $142000.0 (Q4 2014).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | 63,000.00 |
| Jun 30, 2015 | 63,000.00 |
| Mar 31, 2015 | 97,000.00 |
| Mar 31, 2015 | 97,000.00 |
| Dec 31, 2014 | 142,000.00 |
| Dec 31, 2014 | 142,000.00 |
| Sep 30, 2014 | 182,000.00 |
| Sep 30, 2014 | 182,000.00 |
| Jun 30, 2014 | 226,000.00 |
| Jun 30, 2014 | 226,000.00 |
| Mar 31, 2014 | 225,000.00 |
| Mar 31, 2014 | 225,000.00 |
| Dec 31, 2013 | 228,000.00 |
| Dec 31, 2013 | 228,000.00 |
| Sep 30, 2013 | 150,000.00 |
| Sep 30, 2013 | 150,000.00 |
| Jun 30, 2013 | 304,000.00 |
| Jun 30, 2013 | 304,000.00 |
| Mar 31, 2013 | 226,000.00 |
| Mar 31, 2013 | 226,000.00 |
| Dec 31, 2012 | 207,000.00 |
| Dec 31, 2012 | 207,000.00 |
| Sep 30, 2012 | 253,000.00 |
| Sep 30, 2012 | 253,000.00 |
| Jun 30, 2012 | 238,000.00 |
| Jun 30, 2012 | 238,000.00 |
| Mar 31, 2012 | 239,000.00 |
| Mar 31, 2012 | 239,000.00 |
| Dec 31, 2011 | 270,000.00 |
| Dec 31, 2011 | 270,000.00 |
| Sep 30, 2011 | 335,000.00 |
| Sep 30, 2011 | 335,000.00 |
| Jun 30, 2011 | 169,000.00 |
| Jun 30, 2011 | 169,000.00 |
| Mar 31, 2011 | 137,000.00 |
| Mar 31, 2011 | 137,000.00 |
| Dec 31, 2010 | 120,000.00 |
| Dec 31, 2010 | 120,000.00 |
| Sep 30, 2010 | 181,000.00 |
| Sep 30, 2010 | 181,000.00 |